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Ferulic acid is released by microbial hydrolysis in the colon, where butyric acid, a major by-product of
fermentation, constitutes the main energy source for colonic enterocytes. We investigated how varying
concentrations of this short chain fatty acid may inﬂuence the absorption of the phenolic acid. Chronic
treatment of Caco-2 cells with butyric acid resulted in increased mRNA and protein abundance of the
monocarboxylate transporters SLC16A1 (MCT1) and SLC16A3 (MCT4), previously proposed to facilitate
ferulic acid absorption in addition to passive diffusion. Short term incubation with butyric acid only led
to upregulation of MCT4 while both conditions increased transepithelial transport of ferulic acid in the
apical to basolateral, but not basolateral to apical, direction. Chronic treatment also elevated intracellular
concentrations of ferulic acid, which in turn gave rise to increased concentrations of ferulic acid me-
tabolites. Immunoﬂuorescence staining of cells revealed uniform distribution of MCT1 protein in the cell
membrane, whereas MCT4 was only detected in the lateral plasma membrane sections of Caco-2 cells.
We therefore propose that MCT1 may be acting as an uptake transporter and MCT4 as an efﬂux system
across the basolateral membrane for ferulic acid, and that this process is stimulated by butyric acid.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Fermentation of ﬁbre by the gut microbiota results in the pro-
duction of large quantities of short chain fatty acids (SCFA)
amounting tomillimolar concentrations in the colon [1,2]. The SCFA
butyric acid is taken up into colonic enterocytes either by passive
diffusion of the free acid or via the apical uptake transporters
monocarboxylate transporter 1 (MCT1) and sodium coupled
monocarboxylate transporter 1 (SMCT1) [3,4]. SCFA transport by
facilitated diffusion is driven by one of three mechanisms; co-
transport of protons, along the proton gradient created by the
luminal pH of 6e7 (MCT1), transport of sodium ions along theonocarboxylate transporter;
onocarboxylate transporter;
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r Inc. This is an open access articlesodium gradient maintained by basolateral sodium/potassium
pumps (SMCT1), or through heteroexchange of monocarboxylates
[5,6]. After synthesis, the MCT1 transporter is assembled as a het-
erodimer with the chaperone peptide CD147 (basigin) which di-
rects MCT1 insertion into the plasma membrane and the continued
association of the two proteins is essential for correct functioning of
the transporter [7]. No similar association between SMCT1 and a
chaperone peptide has been reported [8].
The SCFAs taken up into the mucosal epithelium constitute the
major energy source for cells of the large intestine [9,10]. Butyric
acid is reported to reduce the risk of colon cancer, protect the
mucosa through stimulation of mucus secretion and tight junction
integrity, and act as an anti-inﬂammatory agent [11,12]. It also in-
creases expression of MCT1 and its chaperone CD147 [13e17]. In
the small intestine, low concentrations of SCFA correlate with lower
MCT1 abundance [18] and in muscle cells, increasing lactate levels
upregulated mitochondrial MCT1 expression as part of a lactate
shuttle protein complex [19]. MCT1 is located on the vascular side
of the epithelium, whereas MCT4 is both intracellular and lumen-
facing, and so could transport SCFA into cells as well as shuttling
SCFA metabolites intracellularly, while in goats, MCT4 wasunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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butyrate [20].
Cereals and whole grain products are rich sources of phenolic
compounds with ferulic acid being one of the most abundant [21].
Many phenolic acids are reported to act as anti-inﬂammatory
agents and reduce the risk of Type 2 diabetes [22e24]. However
only a very small percentage of ferulic acid is present in its free form
as the majority is covalently linked to the carbohydrate matrix of
the plant cell wall, in particular to side chains of the hemicellulose
backbone [25] from which it is cleaved by intestinal esterases
before absorption in the colon [26,27].
Apart from their role as SCFA transporters, MCT1 and SMCT1
have also been suggested as the facilitated component of ferulic
acid uptake [28,29]. We therefore investigated whether there is a
link between physiological butyric acid levels, as present in the
colon, and the uptake of ferulic acid via MCT transport using the
Caco-2 intestinal cell culture model.
2. Materials and methods
2.1. Materials
All cell culture reagents, acetonitrile, formic acid, 3,4-
dimethoxycinnamic acid, ascorbic acid, dihydroferulic acid and
ferulic acid were purchased from Sigma-Aldrich (St. Louis, USA).
Cy3-conjugated donkey anti-mouse IgG and Alexa488-conjugated
donkey anti-rat IgG were obtained from Jackson Immuno
Research (West Grove, USA), ﬂuorescein conjugated wheat germ
agglutinin (WGA) from Vector laboratories (Burlingame, USA),
ProLong Gold anti-fade reagent mounting medium from molecular
probes (Life Technologies, Paisley, UK) and MCT monoclonal anti-
bodies from Santa Cruz Biotechnology (sc-365501, sc-376139) and
Insight Biotechnology (Middlesex, UK). Claudin monoclonal anti-
body (Claudin-1, #37-4900, Invitrogen) and all PCR consumables
were from Life Technologies (Life Technologies, Paisley, UK). Ferulic
acid sulfate was synthesized by Dr Nicolai U. Kraut (University of
Leeds, Leeds, UK) and ferulic acid glucuronide was kindly provided
by Prof. Denis Barron (Nestle Institute of Health Sciences, Lausanne,
Switzerland).
2.2. Cell culture
Caco-2 cells obtained fromATCC (LGC Standards, Middlesex, UK)
were routinely cultured in 5 mM glucose Dulbecco's Modiﬁed Ea-
gle's Medium (DMEM) supplemented with 15% Fetal Bovine Serum
(FBS), 100 units/mL penicillin, 0.1 mg/mL streptomycin and 0.25 mg/
mL Amphotericin B (full medium) at 37 C with 5% CO2 in a hu-
midiﬁed atmosphere. Cells were sub-cultured at ~90% conﬂuence
and seeded on ﬂasks at a density of 1  104 cm2. Cells were used
between passage number 35 and 50.
2.3. Transport studies
Cells were seeded on 6-well Transwell plates (0.4 mM pore size,
polycarbonate, Corning, UK) at a density of 6  104 cm2 and
maintained for 22 days as above in full medium containing 10% FBS
and either 250, 500 or 1000 mM butyric acid dissolved in ethanol
(ﬁnal concentration 0.5% for 250 and 1000 mM and 1% for 500 mM
butyric acid) or the corresponding volume of ethanol for controls.
The medium was changed every other day. For transport studies,
cell monolayers were washed twice with Hank's Balanced Salt So-
lution (HBSS) and the Transepithelial Electrical resistance (TEER) of
the cell layer was measured in HBSS containing 1.8 mM calcium
chloride (þ1.8 mM CaCl2). The average TEER value at day 22 was
~400 U (with a growth area of 4.67 cm2). After TEER measurement,the buffer was replaced with 2 mL 500 mM ferulic acid dissolved in
HBSS þ 1.8 mM CaCl2 in the donor chamber and 2 mL of
HBSS þ 1.8 mM CaCl2 in the receiver chamber. The pH of both so-
lutions was 7.4. For experiments investigating the impact of the
MCT inhibitor phloretin, the compoundwas dissolved in DMSO and
300 mMwas added to the ferulic acid containing transport solution.
The ﬁnal DMSO concentration was 0.1%; controls were supple-
mented with the corresponding volume of solvent. After 60 min
incubation, 1.5 mL samples of the donor and receiver chambers
were collected, acidiﬁed with 10 mM acetic acid and 100 mM
ascorbic acid as antioxidant, 50 mM 3,4-dimethoxycinnamic acid as
internal standard was added and the samples were analysed by LC-
MS/MS. After sample collection, cells werewashed three timeswith
HBSS and lysed with 1000 mL of 80% methanol containing 100 mM
ascorbic acid and 5 mM 3,4-dimethoxycinnamic acid. After vigorous
mixing, cell lysates were centrifuged; the supernatant was dried
under vacuum and reconstituted in 100 mL of 5% acetonitrile, 0.1%
formic acid for chromatographic analysis (LC-MS/MS solvent A).
2.4. HPLC analysis
Aglycone analysis was done on an Agilent 1200 series HPLC
equipped with a diode array detector (DAD). Separation was ach-
ieved on an Agilent ZORBAX Eclipse Plus C18 column
(2.1  100 mm, 1.8 mm). Solvent A consisted of 94.9% MilliQ water,
5% acetonitrile and 0.1% formic acid and solvent B was 94.9%
acetonitrile, 5% MilliQ water and 0.1% formic acid. The solvent
gradient proﬁle was as follows: 0e12 min: linear gradient from 0%
to 50% solvent B; 12e18 min: linear gradient from 50% to 100%
solvent B; 18e20 min: 100% solvent B; 20e24 min: linear gradient
from 100% to 0% solvent B; 24e31 min: 0% solvent B at 0.2 mL/min.
The peak areas determined at 320 nmwere utilised to quantify both
ferulic acid and the internal standard 3,4-dimethoxy-cinnamic acid
by comparison to original standards.
2.5. LC-MS/MS analysis
Samples were analysed for ferulic acid metabolites on an Agilent
6410 LC-MS/MS as described previously [30] with the following
modiﬁcations: solvent A consisted of 95% deionised water, 5%
acetonitrile and 0.5% formic acid, solvent B consisted of 95%
acetonitrile, 5% deionised water and 0.5% formic acid. A solvent
gradient was run with the following proﬁle: 0% solvent B from 0 to
3 min, a linear increase from 5% to 30% solvent B from 3 min to
15 min, 100% solvent B from 15.1 min to 17.5 min and 0% solvent B
from 17.6 min to 21.5 min. Analytes were identiﬁed and quantiﬁed
using original standards based on the following MRM pairs:
m/z ¼ 369/ 113 for ferulic acid glucuronide,
m/z ¼ 273/ 178 for ferulic acid sulfate,
m/z ¼ 195/ 121 for dihydroferulic acid,
m/z ¼ 193/ 178 for ferulic acid and
m/z ¼ 207/ 103 for the internal standard 3,4-dimethoxycinn-
amic acid.
For results shown in Fig. 6B, C and D, the concentrations were
adjusted to the original volume of the corresponding compartment.
The volume of a cell monolayer was estimated by immunoﬂuo-
rescence staining of the cell membrane. The distance between the
apical and basolateral membrane was estimated by confocal mi-
croscopy and was an average of 15 mm from 13 independent ex-
periments.With a growth area of 4.67 cm2 for Transwell inserts, the
volume of a cell monolayer was calculated to be 7 mL. As cell lysates
were reconstituted in 100 mL of solvent A, a 14.3 dilution is taken
into account. For intracellular ferulic acid metabolites the
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this dilution factor. Samples collected from the apical or basolateral
well were injected without any further processing.2.6. Gene expression
Cells were seeded on solid well plates and maintained as for
transport experiments. For gene expression studies, the culture
medium was replaced with medium containing 1000 mM butyric
acid dissolved in ethanol (ﬁnal concentration 0.5%) or the corre-
sponding volume of ethanol for controls. Cells were either incu-
bated with butyric acid for their entire differentiation time of 22
days (chronic) or for 24 h (acute) starting at day 21. Cells were then
washed with ice cold PBS, scraped and mRNA was extracted using
the Ambion RNAqueous kit (AM1912, Ambion, Life Technologies,
USA), according to the manufacturer's protocol. RNA was tran-
scribed to cDNA using the Applied Biosystems high capacity RNA to
cDNA kit (4387406, Life Technologies, USA) and gene expression
was determined by real-time PCR using the Applied Biosystems
TaqMan gene expression assay and gene expression master mix
(4369016, Life Technologies, Foster City, California, USA) according
to the manufacturer's protocol on a StepOnePlus real-time PCR
system (Applied Biosystems, USA). The Applied Biosystems ID of
the primer/probe set for SLC16A1was Hs00161826_m1, for SLC16A3
it was Hs00358829_m1, for SLC16A4 it was Hs01006127_m1, the
probe number for SMCT1 was Hs00377618_m1, for ABCB1
Hs00184500_m1, for ABCC2 Hs00166123_m1, for ABCG2
Hs01053790_m1 and NM_002046.3 for the reference gene GAPDH.
Expression of the gene of interest is presented normalised to the
reference gene GAPDH (multiplexed) and to the expression in un-
treated control cells using the DDCt method.2.7. Immunoﬂuorescence staining
Caco-2 cells were seeded on Millicell cell culture inserts (12-
well, PET 0.4 mm pore size, Millipore) at a density of
6  104 cm2 and maintained for 21 days. For staining, cells wereFig. 1. Impact of butyric acid on ferulic acid transport across differentiated Caco-2 cell
monolayers. (A) Impact of incubation time and concentration of butyric acid compared
with vehicle-treated controls. Cells were either incubated for their entire differentia-
tion time of 22 days (chronic) or for 24 h starting at day 21 after seeding (acute).
Butyric acid was dissolved in ethanol (ﬁnal concentration 0.5% for 250 and 1000 mM
and 1% for 500 mM butyric acid). Controls were incubated with the equivalent amount
of ethanol for the corresponding time. (B) Direction speciﬁc effect of 1000 mM butyric
acid on transport of ferulic acid. (n ¼ 6; * ¼ p  0.05).ﬁxed with 4% para-formaldehyde in PBS and incubated with WGA
for 10 min. Following permeabilisation with 0.1% Triton-X100 cells
were incubated either with MCT1 or MCT4 antibody at a dilution of
1:50 for 1 h at room temperature. After washing with PBS, cells
were further incubated with Cy3-conjugated donkey anti-mouse
IgG at a 1:300 dilution. Cell layers were stained with 0.2 mg/mL
DAPI and mounted on microscopy slides with ProLong Gold anti-
fade reagent mounting medium and imaged using a Zeiss LSM510
confocal microscope.
2.8. Protein analysis
For protein detection, Caco-2 cells grown on Transwell plates as
before were washed with ice cold PBS, scraped and lysed in Bicine-
Chaps buffer (ProteinSimple) containing 1% protease inhibitor
cocktail. The lysate was centrifuged at 14,000 g for 10 min and the
total protein concentration of the supernatant was determined by
BCA microplate assay according to the manufacturer's instructions
(ThermoFisher Scientiﬁc, UK). For analysis of MCT1 and MCT4
protein, the ProteinSimple ‘WES’ system was used. Samples were
denatured by incubation with 0.1 sample buffer (ProteinSimple)
at 37 C for 20 min. Claudin1 (1:50) was used as a loading control
and run in the same capillary as MCT1 (1:25) or MCT4 (1:25)
following optimisation (Fig. 4). The primary antibody incubation
was 1 h. A standard curve was constructed with different amounts
of Caco-2 cell lysate to test linearity of both antibodies and a
loading sample concentration of 0.5 mg/ml was used as found
optimal for signals of all antibodies (Fig. 4).
2.9. Statistics
All values shown are the mean of three to six independent
experiments± standard error of themean, as indicated in the ﬁgure
legends. For analysis of statistical signiﬁcance, independent sam-
ples Student's t-test was employed and analysis carried out by SPSS
Statistics (v22, IBM).
3. Results
The impact of increasing concentrations of butyric acid on
ferulic acid transport was investigated using the intestinal Caco-2
cell culture model. Only the highest concentration of 1000 mM
butyrate was able to signiﬁcantly modulate ferulic acid uptake, andFig. 2. (A) Impact of phloretin (300 mM) on apical to basolateral transport of ferulic
acid across Caco-2 monolayers chronically supplemented with butyric acid (1000 mM).
(B) Impact of chronic and acute butyric acid supplementation on SLC16A1 (MCT1) and
SLC16A3 (MCT4) mRNA (n ¼ 6; * ¼ p  0.05).
Fig. 3. Antibody validation for protein analysis of MCT1 and MCT4 by ProteinSimple WES system. (A) Pherogram view of 1 mg/ml of Caco-2 whole cell lysate analysed for MCT1
alone and of various amounts of Caco-2 whole cell lysate analysed for MCT1 when run with claudin in the same capillary for standard curve construction. (B) Pherogram view of
1 mg/ml of Caco2 whole cell lysate analysed for MCT4 alone and of various amounts of Caco-2 whole cell lysate analysed for MCT4 when runwith claudin-1 in the same capillary for
standard curve construction. (C) Standard curve for MCT1 and claudin-1 run in the same capillary and MCT4 and claudin-1 run in the same capillary in Caco-2 whole cell lysate. (D)
Lane view of different amounts of whole cell lysate analysed for standard curve construction. NS denotes non-speciﬁc interactions of the MCT1, MCT4 antibodies with the ﬂuo-
rescence standards used in the ProteinSimple WES system.
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Fig. 4. Effect of acute and chronic butyrate treatment on MCT1 and MCT4 protein levels in Caco-2 cells detected with the ProteinSimple WES system. (A) Pherogram view of a
representative biological replicate for control and chronic treated butyrate samples analysed for MCT1 and MCT4. (B) Lane view of two representative biological replicates for
control and butyrate acute and chronic treated samples analysed for MCT1 and MCT4. (C) Peak areas of MCT1 and MCT4 protein levels normalised to claudin-1, detected in 0.5 mg/
ml Caco-2 whole lysate after acute or chronic treatment with 1 mM butyrate and controls treated with vehicle only; n ¼ 6, error bars represent standard error of the mean.
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supplementation had a much greater effect than acute treatment
(Fig. 1A). A directional change in transport as shown in Fig. 1Bargues against a change in passive diffusion and suggests that
transporters are involved, possibly MCTs, as previously hypoth-
esised [3,4]. In addition, the presence of 300 mM phloretin (an MCT
Fig. 5. Indirect immunoﬂuorescence detection of MCT1 and MCT4 in differentiated Caco-2 monolayers. Cells were incubated with DAPI, membrane marker wheat germ agglutinin
(WGA) and either mouse anti-hMCT1 (rows A to C) or mouse anti-hMCT4 (rows D to F) primary antibody and Cy3-conjugated donkey anti-mouse secondary antibody. MCT is shown
in red, appearing orange when co-localising with WGA shown in green and appearing purple when co-localising with DAPI shown in blue. Row G shows control cell layers
incubated with DAPI and secondary antibody only. Scale bars (5 mm) are shown in the lower left corner of DAPI images. Scale bar in row A applies to all images in row A, B and C,
scale bar in row D applies to all images in row D, E and F and scale bar in row G applies to row G only (n ¼ 3).
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pre-treatment, indicating that an MCT member is involved in the
increase of ferulic acid transport (Fig. 2A). MCT1mRNA (Fig. 2B) and
protein levels (Figs. 3 and 4) were higher following chronic but not
acute treatment, whereas for MCT4 changes were signiﬁcant after
both treatments; MCT5 mRNA was not affected, and no SMCT
mRNA was detected by droplet digital PCR analysis (ddPCR, Bio-
Rad, Hemel Hempstead, UK, data not shown).
To further elucidate the role of MCT1 and 4, indirect immuno-
ﬂuorescence staining of Caco-2 cell monolayers was performed
(Fig. 5). MCT1 protein (in red) was detected in the plasma mem-
brane on the apical, lateral and basal side, co-localising with the
plasma membrane marker, WGA (shown in green, appearing or-
ange in the merged ﬂuorescence images when co-localising withred MCT1). MCT1 was also detected in the nuclear envelope, co-
localising with DAPI (shown in blue, appearing purple in merged
images when co-localising with red MCT1). MCT4 was mainly
localised in the lateral plasma membrane with only very low signal
originating from the apical or basal membrane. No intracellular
signal was detected.
In addition to the transport of ferulic acid, the impact of chronic
and acute butyric acid on ferulic acid metabolism in Caco-2 cells
was investigated. Fig. 6 shows concentrations of the three major
ferulic acid metabolites (ferulic acid sulfate, dihydroferulic acid and
ferulic acid glucuronide) for both uptake (a/ b) and efﬂux (b/ a)
transport. Concentrations were adjusted for the original volume of
the sample as stated in the experimental section. All metabolites
were more abundant in the basolateral well compared to the apical
Fig. 6. Ferulic acid metabolism by Caco-2 cells. (A) LC-MS/MS chromatogram of equimolar concentrations of analytes (1000 mM). a ¼ ferulic acid glucuronide (m/z ¼ 369/ 113),
b ¼ ferulic acid sulfate (m/z ¼ 273/ 178), c ¼ dihydroferulic acid (m/z ¼ 195/ 121), d ¼ ferulic acid (m/z ¼ 193/ 178). (B) Concentration of metabolites detected in apical,
basolateral and cell lysate samples after ferulic acid (500 mM) transport in uptake (a/ b) or efﬂux (b/ a) direction. (C) Intracellular ferulic acid concentrations after 1 h uptake or
efﬂux transport across cells chronically treated with butyric acid (1000 mM). (D) Change in metabolite production after acute or chronic butyric acid (1000 mM) treatment of Caco-2
cells, expressed in fold changes compared with control condition without butyric acid (n ¼ 6; * ¼ p  0.05).
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Dihydroferulic acid was the predominant metabolite in the donor
and acceptor wells while ferulic acid sulfate was the principal
metabolite intracellularly, reaching concentrations of up to 9 mM.
Metabolite concentrations were higher when ferulic acid was
applied to the basolateral side (b/ a) than the apical (a/ b), and
this difference could be explained by the increase in the intracel-
lular concentration of the ferulic acid which was further ampliﬁed
by the butyric acid supplementation (Fig. 6C).
Chronic butyric acid supplementation had a pronounced impact
on metabolism when compared to the acute treatment (Fig. 6D).
Acute supplementation increased ferulic acid sulfate levels on the
basolateral side and dihydroferulic acid on the apical side when
ferulic acid was applied apically, and decreased intracellular levels
of ferulic acid glucuronide when applied basolaterally. With
chronic butyric acid supplementation, levels of all metabolites
increased, except for apical levels of ferulic acid sulfate. To inves-
tigate whether these changes in ferulic acid metabolites could be
linked to effects on apical efﬂux transporters following the butyric
acid treatment, mRNA levels of the most abundant apical ATP-
binding cassette transporters in Caco-2 cells, ABCB1, ABCC2 andABCG2, were measured (Fig. 7). Gene expression of ABCG2 was
signiﬁcantly increased after chronic butyric acid treatment,
whereas ABCC2 expression was marginally but signiﬁcantly
reduced.4. Discussion
MCT1 acts either as a symporter, facilitating proton coupled
transport of monocarboxylates, or as an antiporter exchanging one
monocarboxylate against another without proton movement [7].
MCT1 expression increases in the presence of butyric acid, a mi-
crobial metabolite reaching high concentrations of up to ~25mM in
the colon [2]. In the current study, pre-treatment of intestinal Caco-
2 cells with 1000 mM butyric acid resulted in increased transport of
ferulic acid in the uptake direction, an effect that was abolished by
the MCT inhibitor phloretin. Ferulic acid is a potential allocrite of
MCT1 and, in the current study, upregulation of MCT1 by chronic
butyric acid supplementation correlated with an increase in ferulic
acid uptake into the cell. However, ferulic acid transport across the
cell monolayer was increased evenwhenMCT1 expressionwas not,
suggesting that other MCT members may be involved. We found
Fig. 7. A. Expression of apical ABC-efﬂux transporters in Caco-2 cells after 22 day
treatment with 1000 mM butyric acid. (n ¼ 5, * ¼ p  0.05). Expression is relative to
GAPDH. B. GAPDH expression. There were no differences in GAPDH expression be-
tween 1 mM butyrate (C4) and control treatment for up to 24 h starting at day 20 after
seeding. There were also no changes when cells were incubated for their entire dif-
ferentiation time of 21 days either when the cells were grown on transwell plates or
solid support dishes: Ct values in solid wells: starting (24 h) control, 16.68 ± 0.15;
butyrate, 16.78 ± 0.19; after 21 days, control 18.38 ± 0.21; butyrate, 18.48 ± 0.30. Ct
values in permeable transwells: starting (24 h) control, 19.59 ± 0.54; butyrate,
19.69 ± 0.34; after 21 days, control 17.74 ± 0.14; butyrate, 17.96 ± 0.23 (n  4).
Fig. 8. Proposed mechanism of ferulic acid transport across Caco-2 monolayers. Metabolites
Dihydroferulic acid. Butyrate is used mainly as an energy source for colonocytes, and selecte
the adjacent transporter or metabolite.
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before [20]. MCT4 is highly expressed in the colon and in Caco-2
cells and also reported to be inhibited by phloretin [3,31,32].
Immunoﬂuorescence staining of Caco-2 cells revealed the presence
of MCT4 solely in the basolateral plasma membrane whereas MCT1
was more uniformly distributed.
Taken together, these results suggest (Fig. 8) that ferulic acid,
applied to either the apical or basolateral side, is taken up into the
cell by MCT1, which is more abundant after chronic butyric acid
treatment, resulting in elevated intracellular concentrations. In
agreement, after acute butyric acid treatment, no increase in
intracellular concentrations was observed as MCT1 levels were not
changed. Hence we hypothesise that MCT1, although also localised
at the apical side, is only able to import ferulic acid into the cell, as
there is no increase in ferulic acid transport to the apical side after
chronic butyric acid supplementation. MCT4, on the other hand,
seems to only transport ferulic acid from the intracellular envi-
ronment to the basolateral side and not in the reverse direction, as
intracellular ferulic acid concentrations remained stable when
ferulic acid was applied to the basolateral side following acute
butyric acid treatment that increased MCT4 levels. The lack of
MCT4 in the apical membrane has the consequence that only apical
to basolateral transport is affected by butyric acid and not baso-
lateral to apical transport. However the observation that MCT1 only
imports and MCT4 only exports ferulic acid contradicts the idea
that both transporters can translocatemonocarboxylates in and out
of the cell, only depending on the concentration gradient of the
allocrite [33]. This could be explained by the fact that bidirectional
transport by MCT1 and MCT4 has mostly been studied in non-
differentiated cell lines and oocytes using small endogenous com-
pounds such as lactic acid, which may follow different transport
kinetics compared to larger molecules such as ferulic acid. The
directionality of transport by MCTs in Caco-2 cells has also been
observed previously; the transport of salicylic acid, another sub-
strate of MCT1 could be inhibited by phloretin in the apical to
basolateral but not in the basolateral to apical direction [34].
Findings from transport experiments are consistent with
changes in metabolism of ferulic acid, after chronic or acute butyricof ferulic acid: FA-OSO3H; ferulic acid sulfate, FA-GlcA; ferulic acid glucuronide, DHFA;
d metabolites are shown for illustrative purposes. Open arrows indicate and increase in
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resulted in increased intracellular ferulic acid concentrations and a
higher rate of formation of ferulic acid metabolites due to substrate
availability. Similarly higher metabolite concentrations were
observed after efﬂux (b/ a) compared to uptake (a/ b) transport
with the only exception being ferulic acid sulfate which decreased
on the apical side with butyric acid supplementation. This could be
due to decreased expression of the apical efﬂux transporter ABCC2,
implying that ferulic acid sulfate may be a substrate for ABCC2.
ABCG2 in comparison was strongly upregulated with butyric acid
treatment and may have contributed to increased efﬂux of ferulic
acid glucuronides or dihydroferulic acid to the apical side.
There are conﬂicting reports regarding the intestinal localisation
of MCT1; detected in only the apical membrane of Caco-2 cells [35]
and of enterocytes in the human large intestine [31]; detected in
only the basolateral [36] membrane of enterocytes in the human
large intestine; detected in the apical membrane of colonocytes
from pig [37] and rat [17], but in the basolateral membrane of
colonocytes from hamster [38] and cow [39]. MCT4 has been
detected in the basolateral membrane of human mucosal cells [31]
but its localisation was found to vary in the ruminant intestine. In
the small intestine MCT4 was detected with high intensity in the
apical and basolateral membranes at the villi tip but basolateral
localisation decreased down the crypt-villus axis with MCT4
located mainly in the apical membrane of crypt cells. In the large
bovine intestine MCT4 distribution was converse, with apical
localisation in villi tips and basolateral localisation in crypts [40]. A
possible explanation for this variation in reports for MCT1 local-
isation in different tissues and cell lines was recently suggested.
Compared to MCT4, which contains a strong C-terminal sorting
signal targeting the protein to the basolateral membrane of
epithelial cells, MCT1 does not contain any sorting signal but is
localised by its chaperone CD147, which bears a signal sequence for
basolateral sorting, as well as a weak apical targeting signal.
Through the tight association between MCT1 and CD147, MCT1 is
additionally targeted to the basolateral membrane in some types of
cells and solely to the apical side in other types such as the retinal
pigment epitheliumwhen the basolateral targeting sequence is not
recognised. CD147 knock down studies have shown that in the
absence of the chaperone, MCT1 and MCT4 proteins are not
detected in the plasma membrane, but instead accumulate in the
Golgi [41,42]. CD147 is highly glycosylated which may also play a
role in its apical or basolateral targeting [43e45].
SMCT1 has also been proposed to facilitate ferulic acid transport
[46] and its presence has been reported in Caco-2 cells [15]. How-
ever we could not detect any SMCT1 mRNA copies even by ddPCR.
The gene expression of drug transporters and metabolizing en-
zymes in Caco-2 cells varies substantially between laboratories
[47], sometimes depending on the cell line origin and culturing
conditions [48]. The absence of SMCT1 in the Caco-2 cells used in
the experiments described here could be consistent with reports of
SMCT1 down-regulation in other colon cancer cell lines. Exon 1 of
SMCT1 was found to be hypermethylated and therefore not
expressed in over 50% of primary colon cancers and adenomas and
in some colon cancer cell lines [49,50].
We conclude a moderate concentration of butyric acid is able to
modulate MCT1 and MCT4 levels, resulting in increased uptake of
ferulic acid into colonocytes and basolateral transport. Our ﬁndings
could potentially translate to higher concentrations of ferulic acid
in systemic circulation in vivo.
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